| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Robotic Surgical Procedures | 17 | 2024 | 536 | 5.860 |
Why?
|
| Bile Duct Neoplasms | 11 | 2024 | 503 | 4.200 |
Why?
|
| Cholangiocarcinoma | 11 | 2024 | 506 | 4.150 |
Why?
|
| Hepatectomy | 29 | 2024 | 1015 | 3.840 |
Why?
|
| Liver Neoplasms | 32 | 2024 | 4843 | 3.400 |
Why?
|
| Laparoscopy | 11 | 2023 | 1304 | 3.210 |
Why?
|
| Biliary Tract Neoplasms | 5 | 2025 | 187 | 2.370 |
Why?
|
| Pancreatic Neoplasms | 30 | 2024 | 5264 | 2.070 |
Why?
|
| Robotics | 5 | 2022 | 366 | 2.000 |
Why?
|
| Colorectal Neoplasms | 17 | 2024 | 3707 | 1.940 |
Why?
|
| Pancreatectomy | 12 | 2024 | 696 | 1.610 |
Why?
|
| Carcinoma, Hepatocellular | 8 | 2024 | 2193 | 1.590 |
Why?
|
| Chemoradiotherapy, Adjuvant | 6 | 2024 | 562 | 1.490 |
Why?
|
| Bile Ducts, Intrahepatic | 8 | 2023 | 333 | 1.440 |
Why?
|
| Gallbladder Neoplasms | 3 | 2023 | 244 | 1.210 |
Why?
|
| Neoadjuvant Therapy | 18 | 2024 | 5247 | 1.100 |
Why?
|
| Green Fluorescent Proteins | 4 | 2010 | 686 | 0.940 |
Why?
|
| Portal Vein | 5 | 2024 | 363 | 0.910 |
Why?
|
| Propensity Score | 2 | 2024 | 772 | 0.900 |
Why?
|
| Neoplasm Staging | 15 | 2022 | 14037 | 0.890 |
Why?
|
| Biliary Tract Surgical Procedures | 4 | 2024 | 44 | 0.890 |
Why?
|
| Humans | 123 | 2025 | 270809 | 0.870 |
Why?
|
| Postoperative Complications | 11 | 2024 | 5681 | 0.860 |
Why?
|
| Insurance | 1 | 2023 | 13 | 0.860 |
Why?
|
| Adenocarcinoma | 12 | 2022 | 7920 | 0.840 |
Why?
|
| Fluorescent Dyes | 5 | 2022 | 464 | 0.830 |
Why?
|
| Retrospective Studies | 49 | 2024 | 39982 | 0.820 |
Why?
|
| Liver | 7 | 2024 | 3061 | 0.800 |
Why?
|
| Hospitals | 3 | 2020 | 482 | 0.800 |
Why?
|
| Cholecystectomy | 2 | 2021 | 118 | 0.770 |
Why?
|
| Embolization, Therapeutic | 3 | 2024 | 605 | 0.750 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2021 | 76 | 0.720 |
Why?
|
| Fluorescence | 7 | 2021 | 197 | 0.720 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 966 | 0.690 |
Why?
|
| Klatskin Tumor | 1 | 2020 | 30 | 0.680 |
Why?
|
| Chemotherapy, Adjuvant | 10 | 2019 | 4007 | 0.670 |
Why?
|
| Carcinoma | 4 | 2012 | 2610 | 0.670 |
Why?
|
| Pancreaticoduodenectomy | 10 | 2023 | 706 | 0.670 |
Why?
|
| Lymph Node Excision | 4 | 2022 | 2068 | 0.660 |
Why?
|
| Nutrition Assessment | 1 | 2020 | 176 | 0.650 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 248 | 0.640 |
Why?
|
| Minimally Invasive Surgical Procedures | 9 | 2024 | 509 | 0.630 |
Why?
|
| Surgery, Computer-Assisted | 3 | 2022 | 257 | 0.620 |
Why?
|
| Diagnostic Imaging | 6 | 2016 | 1175 | 0.620 |
Why?
|
| Malnutrition | 2 | 2020 | 220 | 0.610 |
Why?
|
| Hernia, Abdominal | 1 | 2018 | 41 | 0.600 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2020 | 629 | 0.590 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2022 | 1833 | 0.590 |
Why?
|
| Immunoconjugates | 1 | 2021 | 316 | 0.570 |
Why?
|
| Surgical Wound Infection | 3 | 2023 | 495 | 0.570 |
Why?
|
| Patient Care Planning | 1 | 2019 | 301 | 0.560 |
Why?
|
| Length of Stay | 8 | 2024 | 1998 | 0.540 |
Why?
|
| Lymph Nodes | 6 | 2023 | 3081 | 0.540 |
Why?
|
| Rectal Neoplasms | 5 | 2023 | 1240 | 0.520 |
Why?
|
| Treatment Outcome | 25 | 2024 | 33860 | 0.520 |
Why?
|
| Middle Aged | 39 | 2024 | 90570 | 0.490 |
Why?
|
| Preoperative Care | 2 | 2020 | 1582 | 0.490 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2012 | 232 | 0.480 |
Why?
|
| Pancreatic Cyst | 2 | 2019 | 111 | 0.480 |
Why?
|
| Aged | 35 | 2024 | 73641 | 0.470 |
Why?
|
| Mesenteric Veins | 2 | 2020 | 83 | 0.470 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2019 | 2272 | 0.470 |
Why?
|
| Gastrectomy | 6 | 2024 | 476 | 0.460 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 288 | 0.460 |
Why?
|
| Ultrasonography | 2 | 2019 | 1932 | 0.450 |
Why?
|
| Liver Diseases | 1 | 2019 | 601 | 0.450 |
Why?
|
| Female | 54 | 2025 | 148940 | 0.450 |
Why?
|
| Mice, Nude | 13 | 2022 | 4332 | 0.440 |
Why?
|
| Pancreatic Diseases | 1 | 2014 | 113 | 0.430 |
Why?
|
| Survival Rate | 14 | 2024 | 12535 | 0.430 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2012 | 1117 | 0.420 |
Why?
|
| Thyroid Neoplasms | 3 | 2016 | 1908 | 0.410 |
Why?
|
| Microscopy, Fluorescence | 3 | 2010 | 768 | 0.410 |
Why?
|
| Male | 44 | 2025 | 128522 | 0.400 |
Why?
|
| Lymphatic Metastasis | 6 | 2021 | 4969 | 0.390 |
Why?
|
| Lymphatic System | 1 | 2011 | 53 | 0.380 |
Why?
|
| Drainage | 3 | 2018 | 460 | 0.370 |
Why?
|
| Quality Indicators, Health Care | 2 | 2017 | 355 | 0.370 |
Why?
|
| Skin, Artificial | 1 | 2010 | 19 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 16752 | 0.360 |
Why?
|
| Proportional Hazards Models | 6 | 2024 | 5099 | 0.350 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2024 | 7789 | 0.350 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2024 | 7923 | 0.350 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2010 | 206 | 0.340 |
Why?
|
| Thyroid Gland | 1 | 2012 | 366 | 0.340 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2025 | 3930 | 0.330 |
Why?
|
| Analgesics, Opioid | 4 | 2023 | 1467 | 0.330 |
Why?
|
| Neoplasms, Experimental | 2 | 2010 | 784 | 0.320 |
Why?
|
| Pancreas, Exocrine | 1 | 2009 | 23 | 0.320 |
Why?
|
| Stomach Neoplasms | 5 | 2024 | 2339 | 0.320 |
Why?
|
| Cohort Studies | 9 | 2022 | 9464 | 0.320 |
Why?
|
| United States | 14 | 2024 | 15834 | 0.300 |
Why?
|
| Patient Discharge | 2 | 2023 | 699 | 0.300 |
Why?
|
| Colonic Neoplasms | 4 | 2022 | 1437 | 0.300 |
Why?
|
| SEER Program | 1 | 2012 | 1052 | 0.300 |
Why?
|
| Collagen | 1 | 2010 | 724 | 0.290 |
Why?
|
| Carcinoma, Papillary | 1 | 2010 | 566 | 0.280 |
Why?
|
| Prognosis | 14 | 2024 | 22533 | 0.270 |
Why?
|
| Adult | 23 | 2024 | 82074 | 0.260 |
Why?
|
| Patient Readmission | 2 | 2023 | 571 | 0.260 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2022 | 1301 | 0.260 |
Why?
|
| Disease Models, Animal | 5 | 2025 | 7323 | 0.260 |
Why?
|
| Combined Modality Therapy | 5 | 2021 | 9054 | 0.250 |
Why?
|
| Colonoscopy | 1 | 2009 | 524 | 0.250 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 2986 | 0.240 |
Why?
|
| Neoplasms | 7 | 2024 | 15952 | 0.240 |
Why?
|
| Prospective Studies | 8 | 2024 | 13422 | 0.240 |
Why?
|
| Cell Line, Tumor | 10 | 2022 | 14886 | 0.240 |
Why?
|
| Critical Pathways | 2 | 2022 | 160 | 0.230 |
Why?
|
| Mammography | 1 | 2010 | 1055 | 0.230 |
Why?
|
| Databases, Factual | 5 | 2024 | 2261 | 0.230 |
Why?
|
| Surgical Instruments | 1 | 2024 | 141 | 0.230 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 5332 | 0.230 |
Why?
|
| Anus Neoplasms | 2 | 2018 | 414 | 0.230 |
Why?
|
| Cholangitis | 1 | 2024 | 50 | 0.220 |
Why?
|
| Incisional Hernia | 1 | 2023 | 15 | 0.220 |
Why?
|
| Nutritional Status | 3 | 2020 | 350 | 0.220 |
Why?
|
| Mammaplasty | 1 | 2010 | 714 | 0.220 |
Why?
|
| Bayes Theorem | 3 | 2022 | 1061 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 2 | 2013 | 4470 | 0.210 |
Why?
|
| Mice | 16 | 2025 | 35421 | 0.210 |
Why?
|
| Receptors, Somatostatin | 2 | 2022 | 94 | 0.210 |
Why?
|
| Hypertension, Portal | 1 | 2024 | 131 | 0.210 |
Why?
|
| Breast Neoplasms | 3 | 2021 | 16246 | 0.210 |
Why?
|
| Hospital Costs | 1 | 2024 | 244 | 0.210 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 623 | 0.210 |
Why?
|
| Teaching Rounds | 1 | 2022 | 37 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2019 | 6259 | 0.200 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 701 | 0.200 |
Why?
|
| Predictive Value of Tests | 6 | 2024 | 4966 | 0.200 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 295 | 0.200 |
Why?
|
| Aged, 80 and over | 11 | 2024 | 31117 | 0.200 |
Why?
|
| Hospital Mortality | 2 | 2020 | 1233 | 0.200 |
Why?
|
| Social Class | 1 | 2023 | 317 | 0.190 |
Why?
|
| Pancreatitis, Chronic | 1 | 2022 | 130 | 0.190 |
Why?
|
| Risk Assessment | 5 | 2023 | 6766 | 0.190 |
Why?
|
| Young Adult | 8 | 2021 | 22255 | 0.190 |
Why?
|
| Cholangiography | 1 | 2021 | 35 | 0.190 |
Why?
|
| Animals | 18 | 2025 | 61363 | 0.190 |
Why?
|
| Luminescent Proteins | 3 | 2010 | 299 | 0.190 |
Why?
|
| Deoxycytidine | 3 | 2018 | 1389 | 0.180 |
Why?
|
| Surgical Oncology | 2 | 2020 | 212 | 0.180 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2024 | 382 | 0.180 |
Why?
|
| Coloring Agents | 1 | 2021 | 232 | 0.180 |
Why?
|
| Technology | 1 | 2021 | 100 | 0.180 |
Why?
|
| Liquid Biopsy | 1 | 2021 | 167 | 0.180 |
Why?
|
| Follow-Up Studies | 9 | 2024 | 15280 | 0.170 |
Why?
|
| Indocyanine Green | 1 | 2021 | 125 | 0.170 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 94 | 0.170 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2024 | 1336 | 0.170 |
Why?
|
| Adolescent | 8 | 2021 | 32698 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 2395 | 0.170 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 4320 | 0.170 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 4495 | 0.170 |
Why?
|
| Tumor Burden | 4 | 2021 | 2033 | 0.170 |
Why?
|
| Gallium Radioisotopes | 1 | 2019 | 62 | 0.160 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 1250 | 0.160 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2024 | 906 | 0.160 |
Why?
|
| Neoplasm Transplantation | 3 | 2011 | 1553 | 0.160 |
Why?
|
| Device Removal | 2 | 2018 | 339 | 0.160 |
Why?
|
| Streptozocin | 1 | 2018 | 70 | 0.160 |
Why?
|
| Clinical Enzyme Tests | 1 | 2018 | 26 | 0.150 |
Why?
|
| Fascia | 1 | 2018 | 56 | 0.150 |
Why?
|
| Amylases | 1 | 2018 | 67 | 0.150 |
Why?
|
| Trastuzumab | 1 | 2021 | 743 | 0.150 |
Why?
|
| Disease-Free Survival | 4 | 2021 | 10268 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 657 | 0.140 |
Why?
|
| Incidental Findings | 1 | 2019 | 283 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 4054 | 0.140 |
Why?
|
| Cisplatin | 2 | 2023 | 2509 | 0.140 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 420 | 0.140 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 129 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2025 | 1216 | 0.140 |
Why?
|
| Software | 1 | 2024 | 1358 | 0.140 |
Why?
|
| Mutation | 8 | 2025 | 15922 | 0.140 |
Why?
|
| Nutritional Support | 1 | 2017 | 79 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 536 | 0.140 |
Why?
|
| Fluorouracil | 2 | 2018 | 1990 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 214 | 0.130 |
Why?
|
| Pancreatic Fistula | 3 | 2022 | 102 | 0.130 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 1048 | 0.130 |
Why?
|
| Operative Time | 3 | 2023 | 254 | 0.130 |
Why?
|
| Neuroendocrine Tumors | 2 | 2020 | 656 | 0.130 |
Why?
|
| Radiotherapy Dosage | 1 | 2024 | 4020 | 0.130 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2024 | 277 | 0.130 |
Why?
|
| Confidence Intervals | 1 | 2017 | 747 | 0.130 |
Why?
|
| Patient Selection | 2 | 2020 | 2032 | 0.130 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2016 | 152 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2022 | 2855 | 0.130 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 4839 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 307 | 0.130 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 140 | 0.130 |
Why?
|
| Thyroid Nodule | 1 | 2016 | 92 | 0.120 |
Why?
|
| Quality of Life | 4 | 2019 | 4810 | 0.120 |
Why?
|
| Mice, Transgenic | 4 | 2013 | 4198 | 0.120 |
Why?
|
| Defecation | 1 | 2014 | 58 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2022 | 1333 | 0.110 |
Why?
|
| Comorbidity | 3 | 2019 | 2393 | 0.110 |
Why?
|
| Hospitals, Teaching | 1 | 2014 | 123 | 0.110 |
Why?
|
| Hospital Charges | 1 | 2014 | 87 | 0.110 |
Why?
|
| Radiopharmaceuticals | 1 | 2019 | 1342 | 0.110 |
Why?
|
| Splenectomy | 1 | 2014 | 167 | 0.110 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2019 | 1260 | 0.110 |
Why?
|
| Positron-Emission Tomography | 2 | 2019 | 2199 | 0.100 |
Why?
|
| Survival Analysis | 3 | 2021 | 9281 | 0.100 |
Why?
|
| Disease Progression | 4 | 2013 | 6881 | 0.100 |
Why?
|
| Survivors | 2 | 2016 | 1022 | 0.100 |
Why?
|
| Incidence | 2 | 2023 | 5824 | 0.100 |
Why?
|
| Pain, Postoperative | 3 | 2022 | 663 | 0.100 |
Why?
|
| Chemoradiotherapy | 2 | 2018 | 2038 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 5606 | 0.100 |
Why?
|
| Hospitalization | 1 | 2021 | 2170 | 0.100 |
Why?
|
| Doxorubicin | 1 | 2018 | 3147 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 485 | 0.090 |
Why?
|
| Pancreatitis | 1 | 2014 | 296 | 0.090 |
Why?
|
| Receptor, ErbB-2 | 1 | 2021 | 2659 | 0.090 |
Why?
|
| Xenon | 1 | 2010 | 22 | 0.090 |
Why?
|
| Pseudopodia | 1 | 2010 | 26 | 0.090 |
Why?
|
| Accidents, Traffic | 1 | 2011 | 116 | 0.090 |
Why?
|
| Lighting | 1 | 2010 | 26 | 0.090 |
Why?
|
| Integrin beta1 | 1 | 2011 | 127 | 0.090 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2013 | 318 | 0.090 |
Why?
|
| Subtraction Technique | 1 | 2010 | 143 | 0.090 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2016 | 742 | 0.090 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 284 | 0.090 |
Why?
|
| Whole Body Imaging | 1 | 2010 | 120 | 0.080 |
Why?
|
| Drug Prescriptions | 2 | 2022 | 309 | 0.080 |
Why?
|
| Thrombospondin 1 | 1 | 2009 | 51 | 0.080 |
Why?
|
| Transduction, Genetic | 1 | 2010 | 493 | 0.080 |
Why?
|
| Polymers | 1 | 2010 | 223 | 0.080 |
Why?
|
| Histocytochemistry | 1 | 2009 | 194 | 0.080 |
Why?
|
| Cytoskeleton | 1 | 2010 | 293 | 0.080 |
Why?
|
| Time Factors | 4 | 2018 | 12979 | 0.080 |
Why?
|
| California | 1 | 2009 | 212 | 0.080 |
Why?
|
| Rectum | 2 | 2023 | 480 | 0.080 |
Why?
|
| Biomarkers, Tumor | 3 | 2025 | 10731 | 0.080 |
Why?
|
| Cell Line | 3 | 2010 | 5313 | 0.080 |
Why?
|
| Ascites | 1 | 2009 | 212 | 0.080 |
Why?
|
| Antibodies | 1 | 2011 | 802 | 0.080 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 1054 | 0.070 |
Why?
|
| General Surgery | 1 | 2011 | 334 | 0.070 |
Why?
|
| Wounds and Injuries | 1 | 2011 | 424 | 0.070 |
Why?
|
| Lower Body Negative Pressure | 1 | 2006 | 3 | 0.070 |
Why?
|
| Image Enhancement | 1 | 2010 | 553 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2010 | 1355 | 0.070 |
Why?
|
| Inpatients | 2 | 2022 | 686 | 0.070 |
Why?
|
| Hospitals, Veterans | 1 | 2009 | 370 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 5157 | 0.070 |
Why?
|
| Lipids | 1 | 2010 | 656 | 0.070 |
Why?
|
| Pyrroles | 1 | 2010 | 588 | 0.070 |
Why?
|
| Models, Animal | 1 | 2009 | 657 | 0.070 |
Why?
|
| Gastrointestinal Tract | 1 | 2009 | 322 | 0.070 |
Why?
|
| Risk Factors | 4 | 2023 | 17867 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 663 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 4971 | 0.070 |
Why?
|
| Cell Proliferation | 4 | 2011 | 7233 | 0.060 |
Why?
|
| Exercise Test | 1 | 2006 | 310 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2010 | 589 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 10409 | 0.060 |
Why?
|
| Oxygen Consumption | 1 | 2006 | 418 | 0.060 |
Why?
|
| Betacoronavirus | 2 | 2020 | 514 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 3190 | 0.060 |
Why?
|
| Mastectomy, Segmental | 1 | 2010 | 1050 | 0.060 |
Why?
|
| Indoles | 1 | 2010 | 1029 | 0.060 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 14639 | 0.060 |
Why?
|
| Cell Survival | 1 | 2010 | 3058 | 0.060 |
Why?
|
| Biomarkers | 3 | 2023 | 5050 | 0.060 |
Why?
|
| Abdominal Muscles | 1 | 2023 | 71 | 0.060 |
Why?
|
| Learning Curve | 1 | 2024 | 79 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 1828 | 0.050 |
Why?
|
| Liver Regeneration | 1 | 2024 | 133 | 0.050 |
Why?
|
| Pancreaticojejunostomy | 1 | 2022 | 14 | 0.050 |
Why?
|
| Bilirubin | 1 | 2024 | 226 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2024 | 322 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2010 | 1837 | 0.050 |
Why?
|
| Age Factors | 1 | 2012 | 5443 | 0.050 |
Why?
|
| Organ Size | 1 | 2024 | 688 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 1587 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 5053 | 0.050 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2022 | 77 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2013 | 7054 | 0.050 |
Why?
|
| Observer Variation | 1 | 2024 | 709 | 0.050 |
Why?
|
| Hepatic Artery | 1 | 2022 | 255 | 0.050 |
Why?
|
| Genes, APC | 1 | 2021 | 72 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 276 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 247 | 0.050 |
Why?
|
| Pandemics | 2 | 2020 | 1608 | 0.050 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2020 | 80 | 0.050 |
Why?
|
| Registries | 2 | 2019 | 2212 | 0.040 |
Why?
|
| Operating Rooms | 1 | 2021 | 130 | 0.040 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2020 | 43 | 0.040 |
Why?
|
| Radiology, Interventional | 1 | 2021 | 141 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2023 | 652 | 0.040 |
Why?
|
| Texas | 2 | 2021 | 6445 | 0.040 |
Why?
|
| Digestive System Neoplasms | 1 | 2020 | 79 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2021 | 315 | 0.040 |
Why?
|
| Consensus | 1 | 2024 | 1113 | 0.040 |
Why?
|
| Pain | 2 | 2023 | 1701 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 2659 | 0.040 |
Why?
|
| Patient Safety | 1 | 2024 | 612 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2024 | 697 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2019 | 291 | 0.040 |
Why?
|
| Chelating Agents | 1 | 2019 | 131 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 669 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 6193 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 252 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2022 | 8607 | 0.040 |
Why?
|
| Colon, Ascending | 1 | 2018 | 14 | 0.040 |
Why?
|
| Neomycin | 1 | 2018 | 47 | 0.040 |
Why?
|
| Colon, Sigmoid | 1 | 2018 | 43 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 819 | 0.040 |
Why?
|
| Genes, ras | 1 | 2021 | 678 | 0.040 |
Why?
|
| Cathartics | 1 | 2018 | 40 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 12045 | 0.040 |
Why?
|
| Citric Acid | 1 | 2018 | 53 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2019 | 920 | 0.040 |
Why?
|
| Anal Canal | 1 | 2018 | 237 | 0.040 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 38 | 0.040 |
Why?
|
| Anastomotic Leak | 1 | 2018 | 83 | 0.040 |
Why?
|
| Metronidazole | 1 | 2018 | 170 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2024 | 1420 | 0.030 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 207 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2021 | 1140 | 0.030 |
Why?
|
| Infant | 1 | 2012 | 14003 | 0.030 |
Why?
|
| Prevalence | 1 | 2024 | 3395 | 0.030 |
Why?
|
| Stomach | 1 | 2019 | 396 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2012 | 17083 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2021 | 2136 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 2356 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 824 | 0.030 |
Why?
|
| Cytokines | 1 | 2023 | 2804 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 2300 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 1592 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 879 | 0.030 |
Why?
|
| Pancreas | 1 | 2017 | 739 | 0.030 |
Why?
|
| Thyroidectomy | 1 | 2016 | 489 | 0.030 |
Why?
|
| Peritoneal Neoplasms | 1 | 2020 | 866 | 0.030 |
Why?
|
| Cell Movement | 2 | 2011 | 2468 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 1249 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2016 | 690 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 2344 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 5759 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 2363 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 1188 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 3054 | 0.020 |
Why?
|
| Child | 1 | 2012 | 30572 | 0.020 |
Why?
|
| Focal Adhesions | 1 | 2010 | 44 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2017 | 912 | 0.020 |
Why?
|
| Phosphotyrosine | 1 | 2010 | 124 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2011 | 289 | 0.020 |
Why?
|
| Sarcoma | 1 | 2020 | 1851 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2021 | 12036 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 590 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2011 | 425 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 1023 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 1072 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 1094 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 1489 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 1695 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2010 | 487 | 0.020 |
Why?
|
| Actins | 1 | 2010 | 586 | 0.020 |
Why?
|
| Hypergravity | 1 | 2006 | 1 | 0.020 |
Why?
|
| Weight-Bearing | 1 | 2006 | 64 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 1931 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4396 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 1623 | 0.010 |
Why?
|
| Computational Biology | 1 | 2010 | 1295 | 0.010 |
Why?
|
| Base Sequence | 1 | 2010 | 5406 | 0.010 |
Why?
|
| Heart Rate | 1 | 2006 | 744 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 2478 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2009 | 2413 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 3582 | 0.010 |
Why?
|
| Melanoma | 1 | 2020 | 5601 | 0.010 |
Why?
|
| Proteomics | 1 | 2010 | 1426 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2010 | 2114 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 5924 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2009 | 6344 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 5146 | 0.010 |
Why?
|